Home/Filings/4/0001765581-25-000026
4//SEC Filing

Iannone Robert 4

Accession 0001765581-25-000026

CIK 0001232524other

Filed

Mar 6, 7:00 PM ET

Accepted

Mar 7, 6:49 PM ET

Size

8.3 KB

Accession

0001765581-25-000026

Insider Transaction Report

Form 4
Period: 2025-03-05
Iannone Robert
EVP, Global Head of R&D & CMO
Transactions
  • Disposition to Issuer

    Ordinary Shares

    2025-03-05$138.95/sh5,239$727,95989,104 total
  • Sale

    Ordinary Shares

    2025-03-07$138.21/sh5,532$764,57883,572 total
  • Sale

    Ordinary Shares

    2025-03-07$140.00/sh1,548$216,72082,024 total
Footnotes (3)
  • [F1]Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
  • [F2]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • [F3]Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.19 to $138.23. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

Issuer

Jazz Pharmaceuticals plc

CIK 0001232524

Entity typeother

Related Parties

1
  • filerCIK 0001737329

Filing Metadata

Form type
4
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 6:49 PM ET
Size
8.3 KB